Analystreport

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) had its price target lowered by analysts at Smith Barney Citigroup from $260.00 to $234.00.

Reata Pharmaceuticals, Inc. - Class A  (RETA) 
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.reatapharma.com